Investor excitement about smaller medtechs’ technology is unchecked, but these groups will have to deliver on their promises.
The fastest share price growth in medtech is always recorded by small-caps, but Tandem reached a new extreme last year.
Dexcom can capitalise on its new algorithm technology, but is now enmeshed in a tangled web of partnerships.
Smaller medtechs saw impressive share price growth in 2018, but not quite as good as the year before.
Battle of the algorithms.